Earnings Call · Q4 FY2021·2022-03-01

Q4 21EPS -25.66%·Rev n/aQ3 21EPS +87.50%·Rev n/aQ2 21EPS -17.83%·Rev n/aQ1 21EPS +1.91%·Rev n/a⚠ consensus missing

Sarepta Therapeutics, Inc. SRPT

Mary Jenkins — Investor Relations or similar communications role

Doug Ingram — President and Chief Executive Officer

Louise Rodino-Klapac — Head of Research & Development or similar scientific leadership role

Dallan Murray — Chief Commercial Officer

Ian Estepan — Chief Accounting Officer or similar financial role

−10.9%1d on move date−10.8% vs SPY3d−13.5%5d−16.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SRPT calls or request research access.

More SRPT calls Browse calls Request research access